I am a
Home I AM A Search Login

Papers of the Week

Papers: 7 Nov 2020 - 13 Nov 2020

Human Studies, Pharmacology/Drug Development


Pain Res Manag


Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.


Bergese S, Berkowitz R, Rider P, Ladouceur M, Griffith S, Segura Vasi A, Cochrane K, Wase L, Demitrack MA, Habib AS
Pain Res Manag. 2020; 2020:7492865.
PMID: 33163127.


Oliceridine, an investigational IV opioid, is a first-in-class G-protein selective agonist at the -opioid receptor. The G-protein selectivity results in potent analgesia with less recruitment of -arrestin, a signaling pathway associated with opioid-related adverse events (ORAEs). In randomized controlled studies in both hard and soft tissue models yielding surgical pain, oliceridine provided effective analgesia with a potential for an improved safety and tolerability profile at equianalgesic doses to morphine. The phase 3, open-label, single-arm, multicenter ATHENA trial demonstrated the safety, tolerability, and effectiveness of oliceridine in moderate to severe acute pain in a broad range of patients undergoing surgery or with painful medical conditions warranting use of an IV opioid. This retrospective, observational chart review study compared respiratory depression events associated with oliceridine administration as found in the ATHENA trial to a control cohort treated with conventional opioids.